Hikma Pharmaceuticals and its subsidiaries deliver strong H1 performance
Hikma Pharmaceuticals PLC and its subsidiaries (‘Hikma’ or ‘Group’), the multinational pharmaceutical company, today reports its interim results for the six months ended 30 June 2024. The Group reported revenue growth of 10% (10% in constant currency) to $1.569 billion…